Medical products company Aerocrine has received special 510(k) approval from the US Food and Drug Administration (FDA) for its NIOX VERO to operate wirelessly with BlueTooth technology.
NIOX VERO is the device developed for measuring Fractional Nitric Oxide (FeNO) levels in a clinical setting, which is said to be cost effective to assist in the diagnosis and management of allergic airway inflammation such as asthma.
FDA has granted approval for NIOX VERO for using BlueTooth wireless technology to send FeNO measurements and patient data between the device and the healthcare providers’ computers.
According to Aerocrine, the technology allows the device to go with a healthcare provider to a patient regardless of setting, either in an examination room, a pulmonary function lab or other setting.
In addition, it will help the device to wirelessly transmit patient data to the computer for storage by the healthcare providers on the NIOX Patient software, Aerocrine’s propriety data repository or other electronic medical record software being used by the healthcare providers.